New progress in antitumor research of non-psychoactive cannabidiol

doi:10.3760/cma.j.cn371439-20200615-00089

Abstract

Abstract:

Cannabidiol is one of the most abundant phytocannabinoids in hemp, which has no psychoactive properties and a variety of pharmacological actions in vivo. Several recent studies indicate that cannabidiol possesses antitumor activity, the diversity of its acting receptor distribution and activation mechanism makes it possible to inhibit tumorigenesis in multiple ways via affecting tumor cell proliferation, inducing apoptosis, inhibiting cell invasion and metastasis, anti-angiogenesis and regulating immune response. Further understanding of the mechanism of cannabidiol in tumors may provide new ideas for the development of new antitumor agents.

Key words: Neoplasms, Cannabidiol, Antineoplastic agents

Wang Shuang, Tang Yunyun, Yue Qi. New progress in antitumor research of non-psychoactive cannabidiol[J]. Journal of International Oncology, 2020, 47(10): 619-623.

References 39

[1]	Pacher P, Kogan NM, Mechoulam R. Beyond THC and endocannabinoids[J]. Annu Rev Pharmacol Toxicol, 2020,60:637-659. DOI: 10.1146/annurev-pharmtox-010818-021441.
[2]	Vecera L, Gabrhelik T, Prasil P, et al. The role of cannabinoids in the treatment of cancer[J]. Bratisl Lek Listy, 2020,121(1):79-95. DOI: 10.4149/BLL_2020_012.
[3]	Gamelin FX, Cuvelier G, Mendes A, et al. Cannabidiol in sport: ergogenic or else?[J]. Pharmacol Res, 2020,156:104764. DOI: 10.1016/j.phrs.2020.104764. doi: 10.1016/j.phrs.2020.104764 pmid: 32205233
[4]	Dariš B, Tancer Verboten M, Knez Ž, et al. Cannabinoids in cancer treatment: therapeutic potential and legislation[J]. Bosn J Basic Med Sci, 2019,19(1):14-23. DOI: 10.17305/bjbms.2018.3532.
[5]	Rodrigues T, Sieglitz F, Bernardes GJ. Nature product modulators of transient receptor potential (TRP) channels as potential anti-cancer agents[J]. Chem Soc Rev, 2016,45(22):6130-6137. DOI: 10.1039/c5cs00916b. doi: 10.1039/c5cs00916b pmid: 26890476
[6]	Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels[J]. Front Mol Neurosci, 2019,11:487. DOI: 10.3389/fnmol.2018.00487.
[7]	O'Sullivan SE. An update on PPAR activation by cannabinoids[J]. Br J Pharmacol, 2016,173(12):1899-1910. DOI: 10.1111/bph.13497. doi: 10.1111/bph.13497 pmid: 27077495
[8]	王紫媛, 丁剑午. 孤儿G蛋白偶联受体55的研究进展[J]. 生命的化学, 2015,35(4):509-514. DOI: 10.13488/j.smhx.20150407.
[9]	Ramer R, Schwarz R, Hinz B. Modulation of the endocannabinoid system as a potential anticancer strategy[J]. Front Pharmacol, 2019,10:430. DOI: 10.3389/fphar.2019.00430. doi: 10.3389/fphar.2019.00430 pmid: 31143113
[10]	Khan MI, Sobocińska AA, Czarnecka AM, et al. The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory[J]. Curr Pharm Des, 2016,22(12):1756-1766. DOI: 10.2174/13816128226661512-11094901.
[11]	Śledziński P, Zeyland J, Słomski R, et al. The current state and future perspectives of cannabinoids in cancer biology[J]. Cancer Med, 2018,7(3):765-775. DOI: 10.1002/cam4.1312.
[12]	Ferro R, Adamska A, Lattanzio R, et al. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine[J]. Oncogene, 2018,37(49):6368-6382. DOI: 10.1038/s41388-018-0390-1. doi: 10.1038/s41388-018-0390-1 pmid: 30061636
[13]	Nabissi M, Morelli MB, Amantini C, et al. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner[J]. Int J Cancer, 2015,137(8):1855-1869. DOI: 10.1002/ijc.29573.
[14]	Schwarz R, Ramer R, Hinz B. Targeting the endocannabinoid system as a potential anticancer approach[J]. Drug Metab Rev, 2018,50(1):26-53. DOI: 10.1080/03602532.2018.1428344.
[15]	Fonseca BM, Correia-da-Silva G, Teixeira NA. Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis[J]. J Physiol Biochem, 2018,74(2):261-272. DOI: 10.1007/s13105-018-0611-7. doi: 10.1007/s13105-018-0611-7 pmid: 29441458
[16]	Laezza C, Pagano C, Navarra G, et al. The endocannabinoid system: a target for cancer treatment[J]. Int J Mol Sci, 2020,21(3):747. DOI: 10.3390/ijms21030747.
[17]	Singer E, Judkins J, Salomonis N, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma[J]. Cell Death Dis, 2015,6(1):e1601. DOI: 10.1038/cddis.2014.566.
[18]	Jeong S, Yun HK, Jeong YA, et al. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells[J]. Cancer Lett, 2019,447:12-23. DOI: 10.1016/j.canlet.2019.01.011. doi: 10.1016/j.canlet.2019.01.011 pmid: 30660647
[19]	Jeong S, Kim BG, Kim DY, et al. Cannabidiol overcomes oxaliplatin resistance by enhancing NOS3- and SOD2-induced autophagy in human colorectal cancer cells[J]. Cancers (Basel), 2019,11(6):781. DOI: 10.3390/cancers11060781.
[20]	Zhang X, Qin Y, Pan Z, et al. Cannabidiol induces cell cycle arrest and cell apoptosis in human gastric cancer SGC-7901 cells[J]. Biomolecules, 2019,9(8):302. DOI: 10.3390/biom9080302. doi: 10.3390/biom9080302
[21]	Elbaz M, Nasser MW, Ravi J, et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of cannabidiol in breast cancer[J]. Mol Oncol, 2015,9(4):906-919. DOI: 10.1016/j.molonc.2014.12.010. doi: 10.1016/j.molonc.2014.12.010 pmid: 25660577
[22]	Hinz B, Ramer R. Anti-tumour actions of cannabinoids[J]. Br J Pharmacol, 2019,176(10):1384-1394. DOI: 10.1111/bph.14426.
[23]	Milian L, Mata M, Alcacer J, et al. Cannabinoid receptor expre-ssion in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro[J]. PLoS One, 2020,15(2):e0228909. DOI: 10.1371/journal.pone.0228909. doi: 10.1371/journal.pone.0228909 pmid: 32049991
[24]	García-Morales L, Castillo AM, Tapia Ramírez J, et al. CBD reverts the mesenchymal invasive phenotype of breast cancer cells induced by the inflammatory cytokine IL-1β[J]. Int J Mol Sci, 2020,21(7):2429. DOI: 10.3390/ijms21072429.
[25]	Brown KJ, Laun AS, Song ZH. Cannabidiol, a novel inverse agonist for GPR12[J]. Biochem Biophys Res Commun, 2017,493(1):451-454. DOI: 10.1016/j.bbrc.2017.09.001. pmid: 28888984
[26]	Ramer R, Hinz B. Antitumorigenic targets of cannabinoids—current status and implications[J]. Expert Opin Ther Targets, 2016,20(10):1219-1235. DOI: 10.1080/14728222.2016.1177512. doi: 10.1080/14728222.2016.1177512 pmid: 27070944
[27]	Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications[J]. Pharmacol Ther, 2017,175:133-150. DOI: 10.1016/j.pharmthera.2017.02.041.
[28]	Solinas M, Massi P, Cinquina V, et al. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect[J]. PLoS One, 2013,8(10):e76918. DOI: 10.1371/journal.pone.0076918. doi: 10.1371/journal.pone.0076918 pmid: 24204703
[29]	Ramer R, Fischer S, Haustein M, et al. Cannabinoids inhibit angiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells[J]. Biochem Pharmacol, 2014,91(2):202-216. DOI: 10.1016/j.bcp.2014.06.017.
[30]	Honarmand M, Namazi F, Mohammadi A, et al. Can cannabidiol inhibit angiogenesis in colon cancer?[J]. Comp Clin Pathol, 2019,28:165-172. DOI: 10.1007/s00580-018-2810-6.
[31]	Hegde VL, Singh UP, Nagarkatti PS, et al. Critical role of mast cells and peroxisome proliferator-activated receptor gamma in the induction of myeloid-derived suppressor cells by marijuana cannabidiol in vivo[J]. J Immunol, 2015,194(11):5211-5222. DOI: 10.4049/jimmunol.1401844.
[32]	Kisková T, Mungenast F, Suváková M, et al. Future aspects for cannabinoids in breast cancer therapy[J]. Int J Mol Sci, 2019,20(7):1673. DOI: 10.3390/ijms20071673.
[33]	Dos-Santos-Pereira M, Guimarães FS, Del-Bel E, et al. Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-κB-dependent signaling and glucose consumption[J]. Glia, 2020,68(3):561-573. DOI: 10.1002/glia.23738. doi: 10.1002/glia.23738 pmid: 31647138
[34]	Das S, Kaul K, Mishra S, et al. Cannabinoid signaling in cancer[J]. Adv Exp Med Biol, 2019,1162:51-61. DOI: 10.1007/978-3-030-21737-2_4.
[35]	Likar R, Koestenberger M, Stultschnig M, et al. Concomitant treatment of malignant brain tumours with CBD—a case series and review of the literature[J]. Anticancer Res, 2019,39(10):5797-5801. DOI: 10.21873/anticanres.13783. doi: 10.21873/anticanres.13783 pmid: 31570484
[36]	Dall'Stella PB, Docema MFL, Maldaun MVC, et al. Case report: clinical outcome and image response of two patients with secondary high-grade glioma treated with chemoradiation, PCV, and cannabi-diol[J]. Front Oncol, 2019,8:643. DOI: 10.3389/fonc.2018.00643. doi: 10.3389/fonc.2018.00643 pmid: 30713832
[37]	Sulé-Suso J, Watson NA, van Pittius DG, et al. Striking lung can-cer response to self-administration of cannabidiol: a case report and literature review. SAGE Open Med Case Rep, 2019,7:2050313X19832160. DOI: 10.1177/2050313X19832160. pmid: 31489198
[38]	Kenyon J, Liu W, Dalgleish A. Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol[J]. Anticancer Res, 2018,38(10):5831-5835. DOI: 10.21873/anticanres.12924. doi: 10.21873/anticanres.12924 pmid: 30275207
[39]	Barrie AM, Gushue AC, Eskander RN. Dramatic response to laetrile and cannabidiol (CBD) oil in a patient with metastatic low grade serous ovarian carcinoma[J]. Gynecol Oncol Rep, 2019,29:10-12. DOI: 10.1016/j.gore.2019.05.004. doi: 10.1016/j.gore.2019.05.004 pmid: 31193514